News & events

News & events
<picture><source type="image/webp" srcSet="/static/bd6d2c42e99d69343f6fd727c3137fdd/18e05/Image.webp 740w,/static/bd6d2c42e99d69343f6fd727c3137fdd/81bef/Image.webp 1480w,/static/bd6d2c42e99d69343f6fd727c3137fdd/2d0b8/Image.webp 2960w" sizes="(min-width: 2960px) 2960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2960px) 2960px, 100vw" decoding="async" loading="lazy" src="/static/bd6d2c42e99d69343f6fd727c3137fdd/c9eb6/Image.jpg" srcSet="/static/bd6d2c42e99d69343f6fd727c3137fdd/bbd3f/Image.jpg 740w,/static/bd6d2c42e99d69343f6fd727c3137fdd/087e6/Image.jpg 1480w,/static/bd6d2c42e99d69343f6fd727c3137fdd/c9eb6/Image.jpg 2960w" alt="&lt;p&gt;Image of a middle aged man dressed in a blazer, clapping his hands while smiling.&lt;/p&gt;
"/></picture>

News
17 November 2023Latest
Mendus Announces Nomination Committee for the 2024 Annual General Meeting
Press Release      Stockholm, Sweden, November 17, 2023            Mendus AB (publ: IMMU.ST) announced today that the members of the Nomination Committee have been appointed in accordance with the...
Learn more
13 November 2023
NOTICE OF EXTRAORDINARY GENERAL MEETING IN MENDUS AB (PUBL)
Press Release        Stockholm, Sweden, November 13, 2023                The shareholders of Mendus AB (publ) (the “Company”), reg. no 556629-1786, are hereby invited to the Extraordinary General...
Learn more
9 November 2023
Mendus AB Interim Report January – September 2023
Press Release    Stockholm, Sweden, November 9, 2023        So far in 2023, Mendus has realized significant progress in its corporate development, and we aim to end the year strong    The progress...
Learn more
6 November 2023
Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023
Press Release          Stockholm, Sweden, November 6, 2023                    Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence,...
Learn more
3 November 2023
Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients published in peer-reviewed medical journal
Press Release  Stockholm, Sweden, November 3, 2023    Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients published in peer-reviewed medical journal  Publication...
Learn more
2 November 2023
Mendus announces multiple abstracts to be presented at ASH 2023 including oral presentation on ADVANCE II survival data
Press Release   Stockholm, Sweden, November 2, 2023       Mendus announces multiple abstracts to be presented at ASH 2023 including oral presentation on ADVANCE II survival data   Three abstracts...
Learn more
26 October 2023
Mendus to participate in several investor and industry conferences in November and to host investor webcast and lunch on November 9
Press release    Stockholm, Sweden, October 26, 2023        Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that...
Learn more

Events
29 November 2023
Previous
CEO Erik Manting gives interview to Edison ahead of Mendus’s presentation of updated vididencel survivability data at ASH 2023Learn more
November 2023Previous
Interview with CEO Erik Manting
CEO Erik Manting presents at Redeye Life Science Day 2023 – 23 November 
Learn more
November 2023Previous
Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Mendus will present data from the ongoing Phase 1 ALISON trial in ovarian cancer at SITC 2023. Full abstracts are expected to be published online on Oct. 31, 2023.
Learn more
October 2023Previous
HealthTech Innovation Days
Mendus CEO Erik Manting and CFO Lotta Ferm will participate and present a Company Update at the conference.
Learn more

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89.gbi-1002417752-hMZeP1eCYtYHXnhGCNxP55:before { opacity: 1; background-image: url('/static/755e562542c233156a7bec1f19e2a86b/afb86/new-events-mobile.png'); }

InvestorsAt Mendus, we share a strong commitment to improve the lives of people with cancer.
Investors

News

Mendus Announces Nomination Committee for the 2024 Annual General Meeting

NOTICE OF EXTRAORDINARY GENERAL MEETING IN MENDUS AB (PUBL)

Mendus AB Interim Report January – September 2023

Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023

Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients published in peer-reviewed medical journal

Mendus announces multiple abstracts to be presented at ASH 2023 including oral presentation on ADVANCE II survival data

Mendus to participate in several investor and industry conferences in November and to host investor webcast and lunch on November 9

Events

CEO Erik Manting gives interview to Edison ahead of Mendus’s presentation of updated vididencel survivability data at ASH 2023

Interview with CEO Erik Manting

Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

HealthTech Innovation Days

Investors

Keep up to date